

ZOGENIX

Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2011 Financial Results

February 27, 2012

Conference Call Scheduled for March 8, 2012 at 4:30 pm ET

SAN DIEGO, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the fourth quarter and full year ended December 31, 2011, after the market closes on Thursday, March 8, 2012, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 356-3095 (U.S.) or (617) 597-5391 (International); participant passcode: 51652897.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President and Chief Operating Officer Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning March 8, 2012 at 6:30 p.m. ET (3:30 p.m. PT) until March 15, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 66289262. A replay of the webcast will also be accessible on the Investor Relations website for one month, through April 8, 2012.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release capsule formulation currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. For additional information, please visit www.zogenix.com.

SUMAVEL®, DosePro®, Relday™ and Zohydro™ are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:

Zack Kubow | The Ruth Group
646.536.7020 | zkubow@theruthgroup.com

MEDIA:

Victoria Aguiar | The Ruth Group
646.536.7013 | vaguiar@theruthgroup.com

Zogenix